Skip to main content

Table 1 Demographic and clinical characteristics of patients

From: Noninvasive prediction of node-positive breast cancer response to presurgical neoadjuvant chemotherapy therapy based on machine learning of axillary lymph node ultrasound

Characteristic

Training cohort (Nā€‰=ā€‰310)

Validation cohort (Nā€‰=ā€‰134)

External test cohort (Nā€‰=ā€‰81)

ALN+

(Nā€‰=ā€‰221)

ALNāˆ’

(Nā€‰=ā€‰89)

P

ALN+

(Nā€‰=ā€‰95)

ALNāˆ’

(Nā€‰=ā€‰39)

P

ALN+

(Nā€‰=ā€‰52)

ALNāˆ’

(Nā€‰=ā€‰29)

P

Age (years)

49.74ā€‰Ā±ā€‰10.88

49.21ā€‰Ā±ā€‰9.76

0.691

50.42ā€‰Ā±ā€‰9.82

49.54ā€‰Ā±ā€‰9.31

0.632

50.63ā€‰Ā±ā€‰9.31

50.00ā€‰Ā±ā€‰9.55

0.771

Pathological type, No (%)

Ā Ā 

0.644

Ā Ā 

0.657

Ā Ā 

1.000

ā€‰IDCa

207 (93.67)

81 (91.01)

Ā 

85 (89.47)

37 (94.87)

Ā 

51 (98.08)

29 (100.00)

Ā 

ā€‰ILCb

5 (2.26)

3 (3.37)

Ā 

3 (3.16)

0 (0.00)

Ā 

1 (1.92)

0 (0.00)

Ā 

ā€‰Others

9 (4.07)

5 (5.62)

Ā 

7 (7.37)

2 (5.13)

Ā 

0 (0.00)

0 (0.00)

Ā 

Node long axis (cm)

1.45ā€‰Ā±ā€‰0.68

1.24ā€‰Ā±ā€‰0.54

0.008

1.38ā€‰Ā±ā€‰0.65

1.21ā€‰Ā±ā€‰0.52

0.147

1.59ā€‰Ā±ā€‰0.75

1.47ā€‰Ā±ā€‰0.58

0.436

Node short axis (cm)

0.74ā€‰Ā±ā€‰0.38

0.55ā€‰Ā±ā€‰0.18

<ā€‰0.001

0.72ā€‰Ā±ā€‰0.40

0.53ā€‰Ā±ā€‰0.18

0.003

0.82ā€‰Ā±ā€‰0.35

0.70ā€‰Ā±ā€‰0.28

0.121

Cortical thickness (cm)

0.50ā€‰Ā±ā€‰0.60

0.19ā€‰Ā±ā€‰0.12

<ā€‰0.001

0.52ā€‰Ā±ā€‰0.51

0.20ā€‰Ā±ā€‰0.12

<ā€‰0.001

0.49ā€‰Ā±ā€‰0.34

0.22ā€‰Ā±ā€‰0.22

<ā€‰0.001

Cortical thickening, No (%)

Ā Ā 

<ā€‰0.001

Ā Ā 

0.310

Ā Ā 

0.549

ā€‰Yes

39 (17.65)

3 (3.37)

Ā 

17 (17.89)

4 (10.26)

Ā 

3 (5.77)

0 (0.00)

Ā 

ā€‰No

182 (82.35)

86 (96.63)

Ā 

78 (82.11)

35 (89.74)

Ā 

49 (94.23)

29 (100.00)

Ā 

Medulla absence, No (%)

Ā Ā 

<ā€‰0.001

Ā Ā 

0.054

Ā Ā 

0.001

ā€‰Yes

45 (20.36)

3 (3.37)

Ā 

27 (28.42)

5 (12.82)

Ā 

19 (36.54)

1 (3.45)

Ā 

ā€‰No

176 (79.64)

86 (96.63)

Ā 

68 (71.58)

34 (87.18)

Ā 

33 (63.46)

28 (96.55)

Ā 

T stage, No (%)

Ā Ā 

0.551

Ā Ā 

0.024

Ā Ā 

0.009

ā€‰T1

17 (7.69)

5 (5.62)

Ā 

7 (7.37)

5 (12.82)

Ā 

14 (26.92)

9 (31.03)

Ā 

ā€‰T2

130 (58.82)

47 (52.81)

Ā 

62 (65.26)

17 (43.59)

Ā 

26 (50.00)

19 (65.52)

Ā 

ā€‰T3

64 (28.96)

31 (34.83)

Ā 

22 (23.16)

10 (25.64)

Ā 

12 (23.08)

0 (0.00)

Ā 

ā€‰T4

10 (4.52)

6 (6.74)

Ā 

4 (4.21)

7 (17.95)

Ā 

0 (0.00)

1 (3.45)

Ā 

N stage, No (%)

Ā Ā 

<ā€‰0.001

Ā Ā 

0.001

Ā Ā 

<ā€‰0.001

ā€‰N1

140 (63.35)

78 (87.64)

Ā 

60 (63.16)

37 (94.87)

Ā 

25 (48.08)

26 (89.66)

Ā 

ā€‰N2

43 (19.46)

10 (11.24)

Ā 

18 (18.95)

1 (2.56)

Ā 

11 (21.15)

3 (10.34)

Ā 

ā€‰N3

38 (17.19)

1 (1.12)

Ā 

17 (17.89)

1 (2.56)

Ā 

16 (30.77)

0 (0.00)

Ā 

ER status, No (%)

Ā Ā 

0.038

Ā Ā 

0.011

Ā Ā 

0.401

ā€‰Positive

140 (63.35)

45 (50.56)

Ā 

66 (69.47)

18 (46.15)

Ā 

37 (71.15)

18 (62.07)

Ā 

ā€‰Negative

81 (36.65)

44 (49.44)

Ā 

29 (30.53)

21 (53.85)

Ā 

15 (28.85)

11 (37.93)

Ā 

HER2 status, No (%)

Ā Ā 

0.006

Ā Ā 

0.034

Ā Ā 

0.031

ā€‰Positive

84 (38.01)

43 (48.31)

Ā 

28 (29.47)

19 (48.72)

Ā 

16 (30.77)

16 (55.17)

Ā 

ā€‰Negative

137 (61.99)

46 (51.69)

Ā 

67 (70.53)

20 (51.28)

Ā 

36 (69.23)

13 (44.83)

Ā 

Ki-67ā€‰> 20%, No (%)

Ā Ā 

0.010

Ā Ā 

0.016

Ā Ā 

0.576

ā€‰Yes

116 (52.49)

61 (68.54)

Ā 

44 (46.32)

27 (69.23)

Ā 

32 (61.54)

16 (55.17)

Ā 

ā€‰No

105 (47.51)

28 (31.46)

Ā 

51 (53.68)

12 (30.77)

Ā 

20 (38.46)

13 (44.83)

Ā 

NAC Regimens, No (%)

Ā Ā 

0.152

Ā Ā 

0.280

Ā Ā 

0.161

ā€‰AC-T

41 (18.55)

21 (23.60)

Ā 

16 (16.84)

5 (12.82)

Ā 

9 (17.31)

4 (13.79)

Ā 

ā€‰AC-TH

27 (12.22)

13 (14.61)

Ā 

10 (10.53)

3 (7.79)

Ā 

5 (9.62)

2 (6.90)

Ā 

ā€‰AC-THP

11 (4.98)

2 (2.25)

Ā 

1 (1.05)

1 (2.56)

Ā 

0 (0.00)

0 (0.00)

Ā 

ā€‰AT

22 (9.95)

3 (3.37)

Ā 

18 (18.95)

6 (15.38)

Ā 

6 (11.54)

1 (3.45)

Ā 

ā€‰TAC

77 (34.84)

21 (23.60)

Ā 

31 (32.63)

7 (17.95)

Ā 

22 (42.31)

8 (27.59)

Ā 

ā€‰TCb

5 (2.26)

3 (3.37)

Ā 

3 (3.16)

2 (5.13)

Ā 

0 (0.00)

0 (0.00)

Ā 

ā€‰TCbH

7 (3.17)

5 (5.62)

Ā 

4 (4.21)

3 (7.69)

Ā 

1 (1.92)

0 (0.00)

Ā 

ā€‰TCbHP

15 (6.79)

9 (10.11)

Ā 

4 (4.21)

3 (7.69)

Ā 

2 (3.85)

2 (6.90)

Ā 

ā€‰TH

2 (0.90)

1 (1.12)

Ā 

1 (1.05)

0 (0.00)

Ā 

0 (0.00)

1 (3.45)

Ā 

ā€‰THP

14 (6.33)

11 (12.36)

Ā 

7 (7.37)

9 (23.08)

Ā 

7 (13.46)

11 (37.93)

Ā 
  1. aInvasive ductal carcinoma
  2. bInvasive lobular carcinoma